Methods and pharmaceutical compositions employing S(+)-desmethylselegiline to treat neoplastic diseases or conditions
OwnerAnthony R. DiSantoinventor
Life of this patent
Estimating the term…
Abstract
The application is directed to the treatment of neoplastic diseases or conditions by administering R(−) desmethylselegiline, S(+) desmethylselegiline, or a combination of the two. Neoplastic diseases and conditions responsive to R(−) desmethylselegiline and/or S(+) desmethylselegiline include both malignant and benign neoplasms.
Claims30
A method for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition, comprising administering to the patient R(−)DMS in a dosage regimen effective to inhibit, in whole or in part, occurrence or progression of the neoplastic disease or condition.
A pharmaceutical composition, comprising:
- a) R(−)DMS;
- and
- b) a second therapeutic agent useful in the treatment of a neoplastic disease or condition.
A method for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition, comprising administering to the patient a pharmaceutical composition comprising:
- a) R(−)DMS;
- and
- b) a second therapeutic agent useful in the treatment of a neoplastic disease or condition;
- wherein one or more unit doses of the composition are effective to inhibit, in whole or in part, occurrence or progression of the neoplastic disease or condition.
A method for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition, comprising administering to the patient S(+)DMS in a dosage regimen effective to s inhibit, in whole or in part, occurrence or progression of the neoplastic disease or condition.
A pharmaceutical composition, comprising:
- a) S(+)DMS;
- and
- b) a second therapeutic agent useful in the treatment of a neoplastic disease or condition.
A method for obtaining a selegiline therapeutic effect in a patient with a neoplastic disease or condition, comprising administering to the patient a mixture of R(−)DMS and S(+)DMS in a dosage regimen effective to inhibit, in whole or in part, occurrence or progression of the neoplastic disease or condition.
A pharmaceutical composition, comprising:
- a) a mixture of R(−)DMS and S(+)DMS;
- and
- b) a second therapeutic agent useful in the treatment of a neoplastic disease or condition.
Dependencies are inferred from the claim text.